Bank of America Raises Oscar Health (NYSE:OSCR) Price Target to $25.00

Oscar Health (NYSE:OSCR) had its price objective boosted by Bank of America from $22.00 to $25.00 in a report released on Monday morning, Benzinga reports. They currently have a buy rating on the stock.

Other research analysts also recently issued research reports about the stock. Raymond James assumed coverage on shares of Oscar Health in a research note on Friday, March 22nd. They set an outperform rating and a $20.00 price objective for the company. Wells Fargo & Company upped their price objective on Oscar Health from $20.00 to $24.00 and gave the stock an overweight rating in a report on Thursday, May 9th. The Goldman Sachs Group lifted their target price on Oscar Health from $16.00 to $21.00 and gave the company a neutral rating in a report on Thursday, May 9th. Finally, TheStreet upgraded Oscar Health from a d rating to a c- rating in a research note on Wednesday, February 21st. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and an average target price of $17.67.

Oscar Health Trading Down 4.6 %

Shares of OSCR opened at $22.21 on Monday. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.10 and a quick ratio of 1.10. Oscar Health has a 1-year low of $4.72 and a 1-year high of $23.44. The stock has a market cap of $5.27 billion, a price-to-earnings ratio of -55.52 and a beta of 1.66. The firm has a 50 day simple moving average of $16.98 and a 200-day simple moving average of $13.23.

Oscar Health (NYSE:OSCR) last released its quarterly earnings results on Tuesday, May 7th. The company reported $0.62 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.34. The company had revenue of $2.14 billion during the quarter, compared to analysts’ expectations of $1.99 billion. Oscar Health had a negative return on equity of 5.77% and a negative net margin of 0.82%. The business’s revenue for the quarter was up 45.8% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.18) earnings per share. Equities analysts forecast that Oscar Health will post -0.04 EPS for the current fiscal year.

Hedge Funds Weigh In On Oscar Health

A number of institutional investors have recently added to or reduced their stakes in the company. Beck Bode LLC acquired a new position in shares of Oscar Health in the 1st quarter worth approximately $9,856,000. Bayesian Capital Management LP acquired a new position in Oscar Health in the first quarter worth $1,066,000. First Light Asset Management LLC raised its holdings in shares of Oscar Health by 117.3% during the first quarter. First Light Asset Management LLC now owns 2,102,554 shares of the company’s stock worth $31,265,000 after purchasing an additional 1,134,919 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of Oscar Health by 153.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,978,152 shares of the company’s stock valued at $59,156,000 after buying an additional 2,409,160 shares during the period. Finally, Quadrature Capital Ltd bought a new stake in shares of Oscar Health during the 1st quarter valued at about $1,312,000. Institutional investors and hedge funds own 75.70% of the company’s stock.

Oscar Health Company Profile

Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.